Status:
COMPLETED
Direct Renin Inhibition Effects on Atherosclerotic Biomarkers
Lead Sponsor:
Texas Tech University Health Sciences Center
Conditions:
Coronary Artery Disease
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-85 years
Phase:
PHASE4
Brief Summary
The investigators aim to assess if a new blood pressure medication, aliskiren, reduces various biomarkers of heart disease found in the blood in patients with a history of both heart disease and type ...
Detailed Description
Agents that attenuate the renin angiotensin system (RAS), i.e. angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARB), have shown to have therapeutic benefit in a va...
Eligibility Criteria
Inclusion
- Diagnosis of type 2 diabetes
- Diagnosis of coronary artery disease
- Currently receiving therapy with an ACE-Inhibitor or Angiotensin Receptor Blocker
- Currently receiving antiplatelet therapy and statin therapy
- Baseline blood pressure \> 100/75 mm Hg
- BMI 25-35 kg/m2
Exclusion
- Concurrent calcium channel blocker therapy
- Documented peripheral edema
- Hyperkalemia
- Serum creatinine \> 2.0
- Diagnosed with proteinuria
- Diagnosed with liver dysfunction or serious rheumatological disorder
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2011
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00818779
Start Date
January 1 2008
End Date
August 1 2011
Last Update
December 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Texas Tech University Health Sciences Center
Lubbock, Texas, United States, 79430